172 results about "Nitric oxide synthase" patented technology

The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-β, transforming growth factor-α, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.

The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.

The invention discloses a making method of compound I and drug composition and application to treat tumour, which is 3-cyano quinoline derivant (I) as dual-inhibitor protein kinase of tyrosine and nitric oxide synthase, wherein G1, G2, G3, G4, X, Z and n are defined as instruction.

The present invention describes novel nitrosated and/or nitrosylated potassium channel activators, and novel compositions comprising at least one nitrosated and/or nitrosylated potassium channel activator, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one potassium channel activator, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cardiovascular disorders, cerebrovascular disorders, hypertension, asthma, baldness, urinary incontinence, epilepsy, sleep disorders, gastrointestinal disorders, migraines, irritable bowel syndrome and sensitive skin.

The present invention relates to compounds and methods useful as inhibitors of nitric oxide synthase. Certain compounds of the subject invention have the following structural formula:

wherein T, X, and Y are independently selected from the group consisting of CR⁴, N, NR⁴, S, and O; U is selected from the group consisting of CR¹⁰ and N; V is selected from the group consisting of CR⁴ and N; W and W′ are independently selected from the group consisting of CH₂, CR⁷R⁸, NR⁹, O, N(O), S(O)_q and C(O); n, m and p are independently an integer from 0 to 5; q is 0, 1, or 2; and other substituents are as defined herein. Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention.

It is disclosed here that HMG-CoA reductase inhibitors inhibit the proliferation and cause the death of breast cancer cells by inducing the expression of inducible nitric oxide synthase (iNOS) to promote intracellular nitric oxide formation, which the inventors found to be accomplished through the inhibition of protein geranylgeranylation. The disclosure here enables a new breast cancer treatment strategy that combines the inhibition HMG-CoA reductase or protein geranylgeranylation and the promotion of nitric oxide formation by iNOS.

The invention discloses a transgenic soybean GTS40-3-2 and endogenous and exogenous gene multi-nested fluorescent quantitative PCR (polymerase chain reaction) detection primer combination method. Multiple PCR, nested PCR and fluorescent quantitative PCR are combined, primer design is strictly controlled, the detection process is improved, a multi-nested fluorescent quantitative PCR detection system is built and can quantitatively detect transgenic soybean GTS40-3-2 strains, common exogenous gene NOS (nitric oxide synthase) terminators, CP4-EPSPS, CaMV35S promoters and soybean endogenous genes Lectin, and sensitivity of the method is improved by one order of magnitude as compared with common fluorescent quantitative PCR. The method has the advantages of small template demand quantity, high sensitivity, high flux, strong specificity and the like, and can be applied to rapidly and quantitatively detecting trans-genes. A novel method is provided for rapidly, accurately and quantitatively detecting the trans-genes at high flux.

Advanced Islet Separation Technology incorporates an automated method, automated control methodology, process control interface, and automated apparatus to separate (isolate) and process pancreatic islets in a tissue suspension in physiologic process solution, utilizing microprocessor controllers and computer control and software programming to interface and control the process temperature, process flowrate, percent hydrogen concentration, dissolved oxygen concentration, endotoxin concentration, dissolved nitric oxide concentration, nitric oxide synthase concentration, proteolytic enzyme activity, and pressure of the islet containing physiologic process solution, including real-time process data acquisition and recording of the process variables.

This invention relates to new camphanylidene and phenyl alkyl inositol polyphosphate derivatives that inhibit the absorption of sodium ions in epithelial cells and regulate inducible nitric oxide synthase (iNOS) in macrophages. The invention provides methods for inhibiting sodium ion absorption by epithelial cells and/or regulating inducible nitric oxide synthase (iNOS) in macrophages, by treating epithelial cells or administering to a patient in need of such treatment a therapeutically effective amount of camphanylidene and/or phenyl alkyl inositol polyphosphate compound. Representative camphanylidene and phenyl alkyl inositol polyphosphate compounds include, for example, 1,2-camphanylidene-myo-inositol 3,4,5,6-tetrakisphosphate octalkis (propionoxymethyl) ester (INO-4996), 2,3-camphanylidene-myo-inositol 1,4,5,6-tetrakisphosphate octakis (propionoxymethyl) ester (INO-4984) and 2-O-butyryl-1-O-(3-phenylpropyl)-myo-inositol 3,4,5,6-tetrakisphosphate octakis (propionoxymethyl) ester (INO-4997).

The invention relates to use of a diterpene from a coral, excavatolide B, or an analogue thereof for treating a disease associated with inducible nitric oxide synthase, cyclooxygenase-2 and/or matrix metalloproteinase. The invention also relates to use of a diterpene from a coral, excavatolide B, and an analogue thereof for treating a disease associated with TNF-α and/or IL-6 over-expression.

The invention discloses an anti-inflammatory effective component extract of antrodia cinnamomea sporocarp, a preparation method and application thereof. The preparation method comprises the following steps of: drying the antrodia cinnamomea sporocarp; and extracting the dried antrodia cinnamomea sporocarp by using ethanol, and collecting an ethanol extract to obtain the anti-inflammatory effective component extract of the antrodia cinnamomea sporocarp. In order to achieve the better extraction effect, the method comprises the following steps of: concentrating the ethanol extract further; layering a concentration product by using water and ethyl acetate; and collecting an ethyl acetate extract to obtain the anti-inflammatory effective component extract. The anti-inflammatory effective component extract of the antrodia cinnamomea sporocarp and Antrocamphin A separated from the antrodia cinnamomea sporocarp can reduce the expression of nitric oxide synthase or cycloxygenase 2 to inhibit pro-inflammation molecules from generating.

Triple Tg (megsin/RAGE/iNOS-Tg) was created by crossing megsin-Tg with RAGE/iNOS-Tg. The megsin/RAGE/iNOS-Tg develops marked pathologies of diabetic nephropathy unfound in conventional models at early stages, and various pathological conditions such as glomerular hypertrophy were observed uniformly in the megsin/RAGE/iNOS-Tg mice. In addition, it was also found that animals exhibiting these symptoms were useful as a disease model animal for diabetic nephropathy. Specifically, the disease model animals of the present invention overexpress the megsin gene, a gene encoding the receptor for advanced glycation end-products, and an inducible nitric oxide synthase gene. As a result, accompanying kidney function disorders of glomerular failure develop at early stages.

The invention relates to preparation and application methods of penaeus monodon fermented feed. The preparation method comprises the following steps: respectively carrying out enlarged culture on bacillus licheniformis, lactobacillus plantarum and candida utilis, then mixing in a volume ratio of 1:1:1, adding brown sugar (2g/1000mL) and running water into the mixed bacterial solution under the condition that the ratio of the culture solution to water is 1:80, uniformly mixing, uniformly stirring with penaeus monodon compound feed in a ratio of 2:5, sealing with a plastic film, and fermenting for 18-28 hours, so that the fermented feed is obtained. The invention also provides the application method of the fermented feed. The prepared fermented feed is used for feeding penaeus monodon once a day, and the feeding amount is 20-30% of the daily total feeding amount. The prepared fermented feed can obviously improve nitric oxide synthase activity, superoxide dismutase activity, catalase activity, phenoloxidase activity, glutathione peroxidase activity and total antioxidant capacity of penaeus monodon and obviously reduce the malondialdehyde content; and composition of florae in intestines of the penaeus monodon is obviously improved, and the survival rate of penaeus monodon culture is obviously increased.

The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

The present invention relates to a method for the detection of predisposition to high altitude pulmonary edema (HAPE). It particularly relates to allelic variants of iNOS (inducible nitric oxide synthase) gene, which has been found to be related with the prevalence of HAPE.

Neurotrophin binding to its specific receptors Trk A and p75 leads to the activation of multiple signalling cascades, culminating in neuroprotective and regenerative effects, including neuronal survival and neurite outgrowth. Neurotrophic factors have been used for the treatment of several neurodegenerative diseases. However, their use is limited by their inability to cross the blood-brain barrier, their short half life and their side effects. Small molecule neurotrophin mimetics may be beneficial in treating a number of neurodegenerative disorders. The present invention shows the capacity of nerve growth factor agonist molecules of Formulae I-IV, as defined in the specification, to induce differentiation in PC 12 cells, promote survival in RN22 cells and activate Trk A, IkBa and SAPK/JNK phosphorylation to various extents in both cell lines. In addition these molecules were able to ameliorate acute experimental autoimmune encephalomyelitis (EAE), a multiple sclerosis (MS) animal model, inhibiting brain inflammation and reducing brain damage. We also observed suppression in the production of pro-inflammatory genes like the inducible nitric oxide synthase. These small molecules with NGF agonist activity may be beneficial for MS and other neurodegenerative diseases due to its neuroprotective and immunomodulatory properties.